Nuvation Bio Presented Additional Long-Term Follow-Up Data from Phase 2 Study of Safusidenib in IDH1-Mutant Glioma at the 2026 Society for Neuro-Oncology Annual Meeting
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nuvation Bio (NUVB) presented additional long-term Phase 2 results for safusidenib in patients with grade 2 IDH1-mutant glioma at SNO.
The J201 study enrolled patients who had not received chemotherapy or radiotherapy. At median follow-up of 38.8 months, the centrally assessed confirmed clinical benefit rate was 81.5% and confirmed response rate was 51.9%, including partial and minor responses. Previously reported 36-month progression-free survival was 79%. Median best target-lesion size change was -27.2%; median response duration was not reached, and median time to response was 14.1 months.
Median treatment exposure was 46.7 months, with no new safety signals identified. Treatment-emergent adverse events led to discontinuation in 11.1% of patients. Safusidenib received FDA Fast Track designation in August 2026, and the pivotal Phase 3 SIGMA study is enrolling.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointConfirmed clinical benefit rate was 81.5% in J201, with a 95% confidence interval of 61.9–93.7%.
- Moderate pointConfirmed response rate was 51.9%: 14.8% partial responses (4/27) and 37.0% minor responses (10/27).
- Moderate pointPreviously reported 36-month progression-free survival was 79% at median follow-up of 38.8 months.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Enrolling Phase 3 SIGMA plans approximately 300 patients to evaluate maintenance safusidenib versus placebo after standard-of-care.
- Minor pointMedian best target-lesion size change was -27.2%.
6 minor points
- Minor pointMedian response duration was not reached at data cutoff.
- Minor pointMost patients received treatment for more than 36 months and remained on treatment at data cutoff.
- Minor pointMedian exposure reached 46.7 months, with no new safety signals identified.
- Minor pointFDA granted safusidenib Fast Track designation for IDH1-mutant glioma in August 2026.
- Minor point. Forward-looking: it has not happened yet and may not happen.SIGMA's exploratory, non-pivotal cohort expects approximately 40 patients with chemotherapy- and radiotherapy-naïve grade 3 IDH1-mutant oligodendroglioma.
- Minor point. Forward-looking: it has not happened yet and may not happen.Further evaluation includes Phase 3 G307 where vorasidenib is unavailable and Phase 2 G209 after progression on vorasidenib.
Negative
- Minor pointTreatment-emergent adverse events caused discontinuation in 11.1% (3/27) of patients.
- Minor pointCommon treatment-emergent events included alopecia 59.3%, arthralgia 55.6%, skin hyperpigmentation 51.9%, increased ALT 40.7%, and rash 37.0%.
News Explained
The new findings are from Phase 2 J201; the currently enrolling Phase 3 SIGMA study will compare safusidenib with placebo as maintenance after standard care for high-risk IDH1-mutant astrocytoma, with approximately 300 patients planned in its pivotal portion.
Key Figures
- Follow-up
- Nearly 40 months
- Updated J201 study data
- Confirmed clinical benefit rate
- 81.5% (95% CI: 61.9–93.7)
- Centrally assessed in Grade 2 IDH1-mutant glioma
- Confirmed objective response rate
- 51.9%
- Centrally assessed J201 results
- Median time to response
- 14.1 months
- J201 study
- Median best target lesion change
- -27.2%
- Target lesion size
- Median safusidenib exposure
- 46.7 months
- J201 study
- Treatment discontinuation
- 11.1% (3/27 patients)
- Discontinuation due to treatment-emergent adverse events
Previous Clinical trial Reports
-
Earlier J201 update reported 51.9% response rate and 79.1% 36-month progression-free survival.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
objective response rate medical
progression-free survival medical
treatment-emergent adverse events medical
fast track designation regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
With nearly 40 months of follow-up, additional updated data from J201 study show the confirmed clinical benefit rate was
Patients achieved a median target lesion reduction of
Topline long-term follow-up results were previously announced in July 2026
"Patients with IDH1-mutant glioma are often diagnosed in the prime of their lives and face the long-term uncertainty of disease progression alongside the potential neurocognitive toll and toxicities of radiation and chemotherapy," said Yoshiki Arakawa, M.D., Ph.D., Kyoto University Graduate School of Medicine and lead author of the study. "The mature data presented at SNO—highlighted by a clinical benefit rate above
As previously reported, at a median of 38.8 months follow-up, the J201 study demonstrated a confirmed objective response rate (cORR) of
- The centrally assessed confirmed clinical benefit rate, per Response Assessment in Neuro-Oncology for low grade gliomas criteria, was
81.5% (95% CI: 61.9–93.7). - The centrally assessed cORR was
51.9% , comprising14.8% partial responses (4/27) and37.0% minor responses (10/27). - Median duration of response was not reached at the time of data cutoff. Median time to response was 14.1 months.
- Median best percent change in target lesion size was -
27.2% . - The majority of patients were on treatment for more than 36 months, with treatment still ongoing at the time of data cutoff.
- Median duration of safusidenib exposure was 46.7 months; with longer follow-up, the safety profile of safusidenib remained consistent with previous reports, with no new safety signals identified.
"These compelling long-term data reinforce our confidence in safusidenib's differentiated profile and potential to deliver sustained disease control," said David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio. "As we advance our global pivotal Phase 3 SIGMA study and expand evaluation into more settings, these results bring us closer to our goal of delivering a transformative medicine across the entire continuum of IDH1-mutant glioma."
Safusidenib continued to demonstrate a manageable safety profile consistent with previous reports, with no new safety signals identified. The most common treatment-emergent adverse events (TEAEs) were alopecia (
In August 2026, the
To review the poster, visit the Publications section of Nuvation Bio's website.
About IDH1-mutant Glioma
Gliomas are the most common type of brain cancer in adults worldwide. In the
About Safusidenib
Safusidenib is an investigational, oral, brain-penetrant, selective inhibitor of mutant IDH1. It is being studied in patient populations with significant unmet medical need, including settings where there are limited or no approved targeted treatment options. In Phase 1 and Phase 2 clinical studies, safusidenib demonstrated encouraging clinical activity, including delayed disease progression and durable responses across a range of tumor grades and risk groups, with a favorable risk-benefit profile. These early findings support further investigation of safusidenib in the currently enrolling Phase 3 SIGMA study, as well as in the Phase 3 G307 study in regions where vorasidenib is not yet approved or accessible and the Phase 2 G209 study in patients whose cancer has progressed on vorasidenib.
About the SIGMA (G203) Study
SIGMA is a pivotal Phase 3 study that will evaluate safusidenib compared to placebo as a maintenance therapy after standard-of-care in IDH1-mutant astrocytoma with high-risk features. The pivotal portion of the study will enroll approximately 300 patients.
A separate, exploratory, non-pivotal cohort will evaluate safusidenib in participants with grade 3 IDH1-mutant oligodendroglioma who have not yet received chemotherapy or radiotherapy. The primary endpoint is objective response rate. This cohort is expected to enroll approximately 40 patients.
About Nuvation Bio
Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment with the goal of developing therapies that create a profound, positive impact on patients' lives. Our diverse pipeline includes taletrectinib (IBTROZI®), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; and an innovative drug-drug conjugate (DDC) program.
Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai. For more information, visit www.nuvationbio.com or follow the company on LinkedIn and X (@nuvationbioinc).
Forward-Looking Statements
Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook" and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, our development plans for safusidenib and statements regarding safusidenib's therapeutic potential. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management team of Nuvation Bio and are not predictions of actual performance. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ from those anticipated by the forward-looking statements, including but not limited to the challenges associated with conducting drug discovery and commercialization, and initiating or conducting clinical studies due to, among other things, difficulties or delays in the regulatory process, enrolling subjects or manufacturing or acquiring necessary products; the emergence or worsening of adverse events or other undesirable side effects; risks associated with preliminary and interim data, which may not be representative of more mature data; physician and patient behavior; and competitive developments. Risks and uncertainties facing Nuvation Bio are described more fully in its Form 10-Q filed with the SEC on November 4, 2026, under the heading "Risk Factors," and other documents that Nuvation Bio has filed or will file with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Nuvation Bio disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release.
Nuvation Bio Investor Contact
JR DeVita
ir@nuvationbio.com
Nuvation Bio Media Contact
Kaitlyn Nealy
media@nuvationbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvation-bio-presented-additional-long-term-follow-up-data-from-phase-2-study-of-safusidenib-in-idh1-mutant-glioma-at-the-2026-society-for-neuro-oncology-annual-meeting-302939291.html
SOURCE Nuvation Bio Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Nuvation Bio's Phase 2 safusidenib study show in IDH1-mutant glioma?
J201 showed a centrally assessed confirmed clinical benefit rate of 81.5% and confirmed response rate of 51.9% in patients with grade 2 IDH1-mutant glioma who had not received chemotherapy or radiotherapy. Median best target-lesion size change was -27.2%, and median response duration was not reached at data cutoff.
How long did responses take in Nuvation Bio's safusidenib J201 study?
Median time to response was 14.1 months. Median duration of response had not been reached at data cutoff, with median follow-up of 38.8 months.
What will Nuvation Bio's Phase 3 SIGMA study evaluate?
SIGMA will compare safusidenib with placebo as maintenance therapy after standard-of-care in IDH1-mutant astrocytoma with high-risk features. The pivotal portion will enroll approximately 300 patients. A separate exploratory, non-pivotal cohort will evaluate chemotherapy- and radiotherapy-naïve grade 3 IDH1-mutant oligodendroglioma, with objective response rate as its primary endpoint and expected enrollment of approximately 40 patients.